AI assistant
SCI Investor Presentation 2022
Preview isn't available for this file type.
Download source file
Notes:
公司概況Profile
員工數Employee：203
設立日期：中華民國七十六年九月十八日
Date of establishment: Sep. 18, 1987
資本額Capital：新台幣953佰萬元(NTD 953mn)
營業項目Business：
原料藥API（47.81%）
中間體Intermediate（50.16%）
其他 Other chemicals（2.03%）
Notes:
a production line dedicated
營運概況-IS
Unit: K NTD
Notes:
lackluster October sales
產品組合-Products
Notes:
外租廠房租約於2022年6月底結束
目前產能約30%，努力於年底回復至60%，2023年第一季底全數修復
已收取保險理賠金9億，業外認列理賠收入1.58億，2023年重建完成後結算理賠
2022年產能回復不如預期，營收預期與2021年約當，2023年將有較佳之成長性
受影響鄰廠2020年估計賠償損失5.09億，於2021年及2022年各迴轉損失25佰萬及32佰萬，目前帳列估計負債239佰萬
The plant lease agreement ended at the end of June 2022.
The current production capacity is about 30%, hopefully restored to 60% by the end of this year, and would be completely stored by the end of the first quarter of 2023.
900 million insurance claims have been collected, 158 million of which is recognized as non-operating income. After the reconstruction is completed in 2023, the claims will be settled.
Capacity recovery in 2022 is not as good as expected, so revenue would be close to 2021’s. There would be a better growth in 2023.
In 2020, an estimated loss of 509 million was recognized for compensating affected neighboring factories. 25 million and 32 million were reversed as non-operating income in 2021 and 2022, respectively , after settlements and the remaining estimated debt is 239 million.
Notes:
觀音廠平面圖(Layout of Guanyin Plant)
紅色區域為觀音廠, 其餘為
法蘭摩沙廠區
The part marked in red is
Guanyin Plant and the rest is
Premises of Framosa.
觀音廠外觀(Building exterior)
2022年10月再次投資法蘭摩沙77.75佰萬，持股由40%降為25%，三商投控持有15%
前三季認列法蘭摩沙損失約10佰萬
租賃給法蘭摩沙之70%土地重分類為投資性不動產，仍以成本入帳
2022年10月觀音廠上樑，預計2024年第2季試量產
觀音廠建廠以中期借款因應，目前相關銀行借款214佰萬，負債比率23%
In October 2022, 77.75 million was invested in Framosa for plant construction. The shareholding ratio was reduced from 40% to 25%, and Mercuries Holding held the decreased15%.
By the end of Q3, the loss of Framosa was about 10 million.
70% of the land leased to Framosa was reclassified as investment property and still recorded at acquired cost.
In October 2022, the Guanyin building’s steel structure was completed. The plant is expected to be inaugurated in Q2, 2024.
The Guanyin plant is being funded using medium-term loans. 214 million had been borrowed and the debt ratio was 23%.
| (I) | API | DMF (USA) | CEP (EDQM) | MF (Japan) | DMF (Canada) | CGMP certified?(TFDA) | China DMF |
|---|---|---|---|---|---|---|---|
| 1 | Adenine | 2022 | |||||
| 2 | Articaine Hydrochloride | 2014 | 2014 | 2013 | 2021 | ||
| 3 | Allopurinol | 2011 | 2003 | 2004 | |||
| 4 | Atomoxetine Hydrochloride | 2018 | 2018 | 2016 | |||
| 5 | Bisoprolol Fumarate | 2006 | |||||
| 6 | Brinzolamide | 2015 | 2017 | 2022 (GDP) | |||
| 7 | Clindamycin Palmitate HCl | 2011 | |||||
| 8 | Divalproex Sodium | 2005 | 2010 | 2022 (GDP) | 2010 | ||
| 9 | Duloxetine Hydrochloride | 2011 | 2014 | 2017 | 2016 | 2022 (GDP) | 2013 |
| 10 | Hydroxychloroquine Sulfate | 2014 | 2019 | 2014 | 2014 | 2020 | |
| 11 | Loxoprofen Sodium Hydrate | 2011 | 2012 | ||||
| 12 | Methylphenidate HCl | 2014 | 2022 (GDP) | ||||
| 13 | Pentobarbital Sodium | 2011 | 2022 (GDP) | ||||
| 14 | Probucol | 2004 | 2017 | 2015 | 2022 (GDP) | ||
| 15 | Propafenone Hydrochloride | 2010 | 2012 | 2012 | 2012 | 2022 (GDP) | 2018 |
| 16 | Sodium Valproate | 2019 | 2006 | 2017 | 2022 (GDP) | 2014 | |
| 17 | Thiopental | 2020 | |||||
| 18 | Valproic Acid | 2003 | 2004 | 2008 | 2008 | 2022 | 2019 |
| 19 | Cannabidiol (CBD) | 2020 | 2020 | ||||
| (II) | API intermediate | DMF (USA) | CEP (EDQM) | MF (Japan) | DMF (Canada) | CGMP certified?(TFDA) | |
| 1 | Menthadienol (PMDOL) | 2019 | |||||
| 2 | Olivetol | 2019 | |||||
| 3 | Ethyl Olivetolate | 2019 |
簡 報 完 畢
敬 請 指 教